| Literature DB >> 19807924 |
Matthias Voss1, Marcus Lettau, Ottmar Janssen.
Abstract
BACKGROUND: Fas ligand is a cytotoxic effector molecule of T and NK cells which is characterized by an intracellular N-terminal polyproline region that serves as a docking site for SH3 and WW domain proteins. Several previously described Fas ligand-interacting SH3 domain proteins turned out to be crucial for the regulation of storage, expression and function of the death factor. Recent observations, however, indicate that Fas ligand is also subject to posttranslational modifications including shedding and intramembrane proteolysis. This results in the generation of short intracellular fragments that might either be degraded or translocate to the nucleus to influence transcription. So far, protein-protein interactions that specifically regulate the fate of the intracellular fragments have not been identified.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19807924 PMCID: PMC2763855 DOI: 10.1186/1471-2172-10-53
Source DB: PubMed Journal: BMC Immunol ISSN: 1471-2172 Impact factor: 3.615
Figure 1Schematic representation of FasL and its proline-rich region. A. FasL is a type II membrane protein. In its cytoplasmic N-Terminus, it contains a casein kinase I (CKI) substrate motif and a proline-rich domain (PRD). C-terminal to its transmembrane region (TM), FasL harbors cleavage sites for metalloproteases, a self-assembly (SA) region required for trimerization, several glycosylation sites and the C-terminal receptor binding TNF homology domain (THD). B. The amino acid sequences for the N-terminal cytoplasmic region of human and murine FasL are displayed to highlight the unique proline-rich domain spanning about 30 amino acids.
GST-hFasL(1-80)-interacting SH3 domains.
| P07948 | tyrosine protein kinase Lyn | YK, E | MA | LYM | 1/1 | 43 | 20 | 23 | |
| O43586 | CD2BP1* | CA | MA | LYM | 1/1 | 42 | 14 | 28 | |
| Q92882 | osteoclast-stimulating factor 1 | n.a. | CYT | LYM | 1/1 | 42 | 20 | 22 | |
| Q8WV41 | sorting nexin 33 | A | CYT, MA | UBI | 1/1 | 15 | 4 | 11 | |
| P08631 | tyrosine protein kinase Hck | YK, E | MA, CYT | LYM | 1/1 | 14 | 5 | 9 | |
| P16333 | Nck1 | CA | CYT, MA | LYM | 2/3 | 11 | 7 | 4 | |
| P07947 | tyrosine protein kinase Yes | YK, E | CYT | UBI | 1/1 | 8 | 2 | 6 | |
| P12931 | tyrosine protein kinase Src | YK, E | CYT | UBI | 1/1 | 8 | 5 | 3 | |
| Q9Y5X1 | sorting nexin 9 | A | CYT, MA | LYM | 1/1 | 6 | 6 | 0 | |
| Q7Z6B7 | SLIT-ROBO Rho GAP 1 | R | MA | UBI | 1/1 | 6 | 3 | 3 | |
| A1X283 | SH3 and PX domain containing protein 2B | n.a. | CYT | UBI | 3/4 | 6 | 3 | 3 | |
| A1X283 | SH3 and PX domain containing protein 2B | n.a. | CYT | UBI | 4/4 | 5 | 3 | 2 | |
| Q06187 | tyrosine protein kinase Btk | YK, E | CYT, MA | LYM | 1/1 | 5 | 5 | 0 | |
| Q8TE67 | EGFR kinase substrate 8-like protein 3 | A | CYT | UBI | 1/1 | 4 | 3 | 1 | |
| Q9BRR9 | ARHGAP9 | R | CYT, MA | LYM | 1/1 | 4 | 1 | 3 | |
| Q9UKN7 | Myosin XV | CA | CYT | UBI | 1/1 | 3 | 3 | 0 | |
| O43639 | Nck2 | CA | CYT, MA | LYM | 2/3 | 3 | 2 | 1 | |
| O15117 | Fyn-binding protein | A | CYT, NUC | LYM | 1/1 | 2 | 2 | 0 | |
| P42680 | tyrosine protein kinase Tec | YK, E | CYT | UBI | 1/1 | 2 | 2 | 0 | |
| P02549 | spectrin alpha chain | CA | CYT | ERY | 1/1 | 2 | 2 | 0 | |
| Q9NSI8 | SAM domain-containing protein SAMSN-1 | n.a. | n.a. | LYM | 1/1 | 2 | 2 | 0 | |
| Q8TEC5 | putative E3 ubiquitin protein ligase SH3RF2 | E, R | n.a. | UBI | 3/3 | 2 | 2 | 0 | |
| Q15700 | disks large homology 2 | CA, R | MA | NL | 1/1 | 2 | 1 | 1 | |
| O60504 | vinexin | CA | MA, CYT | NL | 2/2 | 2 | 1 | 1 | |
| O75563 | Src kinase-associated phosphoprotein 2 | CA | MA, CYT | LYM | 1/1 | 2 | 1 | 1 | |
| P46108 | proto-oncogene c-Crk/p38 | A | MA, CYT | NL | 2/1 | 1 | 0 | 1 | |
| Q9NZQ3 | SH3 adapter protein SPIN90 | A, CA | NUC | UBI | 1/1 | 1 | 0 | 1 | |
| Q5TCZ1 | SH3 and PX domain containing protein 2A | A | CYT, MA | UBI | 5/5 | 1 | 0 | 1 | |
| Q9UHR4 | brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1 | CA | CYT | UBI | 3/3 | 1 | 0 | 1 | |
| Q99963 | endophilin-A3 | A | CYT, MA | UBI | 1/1 | 1 | 0 | 1 | |
| O95049 | tight junction protein ZO-3 | A | CYT, MA | UBI | 1/1 | 1 | 0 | 1 | |
| P54284 | voltage-dependent L-type calcium channel subunit beta-3 | E | MA | NL | 1/1 | 1 | 0 | 1 | |
| Q96JB8 | MAGUK p55 subfamily member 4 (isoform 2) | A | CYT | UBI | 1/1 | 1 | 0 | 1 | |
| - | N-Src | - | - | - | 1/1 | 1 | 0 | 1 | |
| P27986 | PI3K regulatory subunit alpha | R, A | MA | LYM | 1/1 | 1 | 0 | 1 | |
| Q6XZF7 | dynamin-binding protein | CA | MA, GOL | UBI | 4/6 | 1 | 0 | 1 | |
| Q8N1I0 | dedicator of cytokinesis protein 4 | R, A | MA | NL | 1/1 | 1 | 1 | 0 | |
| O60229 | kalirin | R, CA | MA | NL | 1/2 | 1 | 1 | 0 | |
| Q6ZN28 | SH3 domain-containing protein 7A5 | TF | CYT, NUC | UBI | 1/1 | 1 | 1 | 0 | |
| O43295 | SLIT-ROBO Rho GAP 3 | R | MA | NL | 2/3 | 1 | 1 | 0 | |
| P06241 | tyrosine protein kinase Fyn | YK, E | MA | LYM | 1/1 | 1 | 1 | 0 | |
| Q16674 | melanoma-derived growth regulatory protein | n.a. | SEC | NL | 1/1 | 1 | 1 | 0 | |
| O75044 | SLIT-ROBO Rho GAP 2 | R | MA | NL | 1/1 | 1 | 1 | 0 | |
| Q9NZM3 | intersectin 2 | A, CA | CYT | LYM | 2/5 | 1 | 1 | 0 | |
| P14598 | p47phox | A | CYT | NL | 1/2 | 1 | 1 | 0 | |
| Q08881 | tyrosine protein kinase Itk | YK, E | MA | LYM | 1/1 | 1 | 1 | 0 | |
| O00305 | voltage-dependent L-type calcium channel subunit beta-4 | E | MA | NL | 1/1 | 1 | 1 | 0 | |
| A6NJZ7 | RIMS-binding protein 3C | n.a. | MA, CYT | n.a. | 2/3 | 1 | 1 | 0 | |
Individual interactors identified by phage display screening are listed according to their Uniprot ID, the respective entry name and the full protein name. In addition, putative protein function and subcellular localization of individual proteins are given according to the respective Uniprot entries. Primary tissue-specific expression is indicated according to the BioGPS database (Genomics Institute, Novartis Research Foundation). The number of hits is given in total and separately for the two applied detergent concentrations. SH3 domains binding to the GST control were excluded from the list.
*Point mutation detected in the provided SH3 domain of CD2BP1
Abbreviations:
Function: YK, tyrosine protein kinase; E, enzymatic acitivity; CA, cytoskeleton-associated (adapter) protein; n.a., not annotated; A, adapter protein; R, regulatory protein; TF, transcription factor
Localization: MA, membrane-associated; CYT, cytosolic; GOL, Golgi; NUC, nuclear; SEC, secreted; n.a., not annotated
Tissue distribution: LYM, lymphoid; UBI, ubiquitous; ERY, erythroid; NL, non-lymphoid; n.a., not annotated
Figure 2Identification of FasL-interacting SH3 domains. Phagemid DNA from transduced clones was isolated and sequenced to unambiguously identify the SH3 domains responsible for interactions with glutathione S-transferase (GST) (white) and GST-hFasL(1-80) (black and grey), respectively. SH3 domains binding unspecifically to the GST moiety were identified by GST library panning. Data are shown from individual experiments with low (0.15% Tween-20, A) and high (0.5% Tween-20, B) detergent concentration. In B, dark and grey boxes show results from two individual panning rounds.
Figure 3FasL precipitates with the SH3 domain of Itk. Pull-down experiment with a GST-Itk SH3 domain fusion protein from whole cell lysates of stably FasL transfected KFL9 and JFL39.1 cells. Lysates were subjected to pull-down experiments with the indicated recombinant proteins. Precipitates were analyzed by SDS-PAGE and Western blot for the presence of FasL using the mAb clone G247-4.
Figure 4The FasL N-terminus precipitates sorting nexin. Pull-down experiment with GST fusion proteins containing the intracellular part of FasL from transiently transfected 293 T cells. Overexpression of sorting nexins in 293 T cells was tested 18 hours post transfection in whole cell lysates (upper panel). The corresponding lysates were subjected to precipitation with GST alone as a control or with a GST fusion protein containing the intracellular region of human FasL (hFasL(1-80)). Precipitated proteins were analyzed by SDS-PAGE and Western blotting using an anti-HA antibody. (EGFP, EGFP-transfected control cells; ctrl, vector-transfected controls).
Figure 5Possible functions of FasL-interacting SH3 domain proteins. FasL transport, storage, surface expression and reverse signaling depend on the proline-rich N-terminal region. Moreover, FasL is processed by ADAM10 generating an N-terminal fragment (NTF) and subsequently RIPped by SPPL2a generating a free intracellular domain (ICD). This ICD might translocate to the nucleus to regulate gene expression. Although several known SH3 domain proteins have been implicated in FasL storage, transport and surface expression, it is largely unknown how exactly the intracellular translocation but also the retrograde signal transduction or FasL degradation are mediated.